 John Rice
Concepts (234)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Models, Statistical | 5 | 2024 | 682 | 1.580 |
Why?
| | Papillomavirus Vaccines | 4 | 2025 | 297 | 1.060 |
Why?
| | Likelihood Functions | 4 | 2026 | 143 | 1.060 |
Why?
| | Papillomavirus Infections | 4 | 2025 | 345 | 1.030 |
Why?
| | Computer Simulation | 4 | 2026 | 1026 | 0.900 |
Why?
| | Time-to-Treatment | 1 | 2026 | 245 | 0.820 |
Why?
| | Vaccination | 10 | 2026 | 1423 | 0.700 |
Why?
| | Oxygen | 6 | 2026 | 995 | 0.640 |
Why?
| | Biometry | 2 | 2017 | 68 | 0.640 |
Why?
| | Vaccination Coverage | 3 | 2026 | 103 | 0.640 |
Why?
| | Critical Illness | 6 | 2025 | 892 | 0.620 |
Why?
| | Pseudomonas Infections | 1 | 2022 | 221 | 0.620 |
Why?
| | Patient Acceptance of Health Care | 7 | 2025 | 886 | 0.600 |
Why?
| | Biostatistics | 1 | 2019 | 19 | 0.590 |
Why?
| | Oxygen Inhalation Therapy | 3 | 2026 | 182 | 0.590 |
Why?
| | Statistical Distributions | 1 | 2017 | 8 | 0.540 |
Why?
| | Mass Screening | 2 | 2022 | 1348 | 0.420 |
Why?
| | Hyperoxia | 3 | 2023 | 99 | 0.380 |
Why?
| | Genetic Testing | 2 | 2026 | 482 | 0.370 |
Why?
| | Cystic Fibrosis | 1 | 2022 | 1158 | 0.350 |
Why?
| | Sarcoma | 2 | 2025 | 205 | 0.350 |
Why?
| | Rhinitis | 2 | 2023 | 171 | 0.320 |
Why?
| | Humans | 48 | 2026 | 144957 | 0.310 |
Why?
| | Sinusitis | 2 | 2023 | 229 | 0.300 |
Why?
| | Breast Neoplasms | 1 | 2022 | 2456 | 0.300 |
Why?
| | Proportional Hazards Models | 2 | 2026 | 1325 | 0.280 |
Why?
| | Brain Injuries, Traumatic | 2 | 2023 | 441 | 0.250 |
Why?
| | Wounds and Injuries | 3 | 2026 | 957 | 0.250 |
Why?
| | HIV Infections | 2 | 2019 | 3154 | 0.240 |
Why?
| | Vaccines | 2 | 2022 | 389 | 0.240 |
Why?
| | Hepatitis A Vaccines | 1 | 2026 | 20 | 0.240 |
Why?
| | Hepatitis A | 1 | 2026 | 25 | 0.240 |
Why?
| | Lung Neoplasms | 3 | 2024 | 2642 | 0.240 |
Why?
| | Vaccination Refusal | 3 | 2021 | 64 | 0.240 |
Why?
| | Hepatitis B Vaccines | 1 | 2026 | 43 | 0.230 |
Why?
| | Parents | 7 | 2025 | 1403 | 0.230 |
Why?
| | Female | 25 | 2026 | 78376 | 0.230 |
Why?
| | Electronic Mail | 1 | 2026 | 61 | 0.230 |
Why?
| | Hepatitis B | 1 | 2026 | 66 | 0.230 |
Why?
| | Bilirubin | 1 | 2025 | 97 | 0.220 |
Why?
| | Meta-Analysis as Topic | 2 | 2017 | 174 | 0.220 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 2 | 2024 | 1182 | 0.220 |
Why?
| | Serum Albumin | 1 | 2025 | 147 | 0.210 |
Why?
| | Gene-Environment Interaction | 2 | 2017 | 180 | 0.210 |
Why?
| | Touch Perception | 1 | 2024 | 20 | 0.200 |
Why?
| | Radiation Injuries | 1 | 2025 | 151 | 0.200 |
Why?
| | Chronic Disease | 4 | 2023 | 1813 | 0.200 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 1 | 2024 | 104 | 0.200 |
Why?
| | Cyclopentanes | 1 | 2023 | 20 | 0.200 |
Why?
| | Safety-net Providers | 2 | 2025 | 126 | 0.200 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2024 | 162 | 0.200 |
Why?
| | Hypoxia | 3 | 2026 | 1199 | 0.200 |
Why?
| | Liver Cirrhosis | 1 | 2025 | 288 | 0.190 |
Why?
| | Workload | 1 | 2024 | 170 | 0.190 |
Why?
| | Survival Analysis | 1 | 2026 | 1385 | 0.190 |
Why?
| | Chemoradiotherapy | 1 | 2024 | 239 | 0.190 |
Why?
| | Adult | 17 | 2026 | 40506 | 0.190 |
Why?
| | Positron-Emission Tomography | 1 | 2024 | 343 | 0.180 |
Why?
| | Out-of-Hospital Cardiac Arrest | 1 | 2024 | 124 | 0.180 |
Why?
| | Pseudomonas | 1 | 2022 | 33 | 0.180 |
Why?
| | Sarcoma, Ewing | 1 | 2023 | 103 | 0.180 |
Why?
| | Stroke | 2 | 2022 | 1258 | 0.180 |
Why?
| | Communication | 2 | 2026 | 967 | 0.180 |
Why?
| | Patient Selection | 1 | 2026 | 719 | 0.170 |
Why?
| | Male | 22 | 2026 | 72406 | 0.170 |
Why?
| | Length of Stay | 2 | 2024 | 1337 | 0.170 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2025 | 372 | 0.170 |
Why?
| | Endothelin-2 | 1 | 2021 | 2 | 0.170 |
Why?
| | Radiosurgery | 1 | 2025 | 401 | 0.170 |
Why?
| | Self Report | 1 | 2025 | 873 | 0.170 |
Why?
| | Bone Remodeling | 1 | 2021 | 71 | 0.170 |
Why?
| | Private Practice | 1 | 2020 | 19 | 0.170 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2025 | 1958 | 0.160 |
Why?
| | Bone Neoplasms | 1 | 2023 | 256 | 0.160 |
Why?
| | Motivation | 1 | 2025 | 610 | 0.160 |
Why?
| | Clinical Trials as Topic | 1 | 2026 | 1054 | 0.160 |
Why?
| | Influenza Vaccines | 2 | 2025 | 529 | 0.160 |
Why?
| | Prescription Drugs | 1 | 2022 | 111 | 0.160 |
Why?
| | Data Interpretation, Statistical | 2 | 2026 | 372 | 0.160 |
Why?
| | Guideline Adherence | 2 | 2022 | 589 | 0.160 |
Why?
| | Cardiopulmonary Resuscitation | 1 | 2024 | 342 | 0.160 |
Why?
| | Burns | 1 | 2025 | 377 | 0.160 |
Why?
| | Biological Products | 1 | 2023 | 252 | 0.150 |
Why?
| | Stakeholder Participation | 1 | 2020 | 84 | 0.150 |
Why?
| | Pyrimidines | 1 | 2023 | 533 | 0.150 |
Why?
| | Community Participation | 1 | 2020 | 132 | 0.150 |
Why?
| | Diet, High-Fat | 1 | 2021 | 261 | 0.150 |
Why?
| | Mentoring | 1 | 2022 | 166 | 0.150 |
Why?
| | Intensive Care Units | 2 | 2025 | 916 | 0.150 |
Why?
| | Oximetry | 3 | 2026 | 126 | 0.140 |
Why?
| | Prospective Studies | 8 | 2024 | 7997 | 0.140 |
Why?
| | Liver Neoplasms | 1 | 2025 | 783 | 0.140 |
Why?
| | Child | 9 | 2025 | 22657 | 0.140 |
Why?
| | Health Knowledge, Attitudes, Practice | 6 | 2024 | 1416 | 0.140 |
Why?
| | Hospitalists | 1 | 2023 | 266 | 0.140 |
Why?
| | Middle Aged | 13 | 2026 | 35928 | 0.140 |
Why?
| | Disease Progression | 2 | 2025 | 2852 | 0.140 |
Why?
| | Plant Extracts | 1 | 2019 | 187 | 0.130 |
Why?
| | Reminder Systems | 1 | 2019 | 141 | 0.130 |
Why?
| | Health Risk Behaviors | 1 | 2017 | 15 | 0.130 |
Why?
| | Diagnostic Self Evaluation | 1 | 2017 | 24 | 0.130 |
Why?
| | Medical Marijuana | 1 | 2019 | 123 | 0.130 |
Why?
| | Brain Injuries | 1 | 2023 | 508 | 0.130 |
Why?
| | Homosexuality, Male | 1 | 2019 | 222 | 0.130 |
Why?
| | Models, Genetic | 2 | 2017 | 536 | 0.130 |
Why?
| | Drug Resistant Epilepsy | 1 | 2019 | 137 | 0.130 |
Why?
| | Colorado | 5 | 2026 | 4564 | 0.130 |
Why?
| | Ultrasonic Waves | 1 | 2017 | 10 | 0.130 |
Why?
| | Adolescent | 8 | 2025 | 22453 | 0.130 |
Why?
| | Respiratory Tract Infections | 1 | 2021 | 398 | 0.130 |
Why?
| | Anticonvulsants | 1 | 2019 | 242 | 0.130 |
Why?
| | Paenibacillus | 1 | 2016 | 1 | 0.130 |
Why?
| | Endo-1,4-beta Xylanases | 1 | 2016 | 2 | 0.130 |
Why?
| | Xylans | 1 | 2016 | 3 | 0.130 |
Why?
| | Liver | 1 | 2025 | 1888 | 0.120 |
Why?
| | Glycoside Hydrolases | 1 | 2016 | 39 | 0.120 |
Why?
| | Text Messaging | 1 | 2019 | 182 | 0.120 |
Why?
| | Clinical Competence | 1 | 2024 | 1244 | 0.120 |
Why?
| | Patient Discharge | 1 | 2023 | 983 | 0.120 |
Why?
| | Referral and Consultation | 1 | 2022 | 853 | 0.120 |
Why?
| | Probability | 1 | 2017 | 312 | 0.120 |
Why?
| | Longitudinal Studies | 2 | 2025 | 2947 | 0.120 |
Why?
| | Capillaries | 1 | 2017 | 124 | 0.120 |
Why?
| | Physicians | 1 | 2024 | 940 | 0.120 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2022 | 2584 | 0.110 |
Why?
| | Influenza, Human | 1 | 2021 | 617 | 0.110 |
Why?
| | Logistic Models | 2 | 2017 | 2119 | 0.110 |
Why?
| | Pneumonia | 1 | 2021 | 631 | 0.110 |
Why?
| | Emergency Medical Services | 1 | 2022 | 696 | 0.110 |
Why?
| | Recurrence | 1 | 2017 | 1135 | 0.100 |
Why?
| | Sleep | 1 | 2021 | 901 | 0.100 |
Why?
| | Healthcare Disparities | 1 | 2021 | 728 | 0.100 |
Why?
| | Retrospective Studies | 8 | 2024 | 17101 | 0.100 |
Why?
| | Cholesterol, HDL | 1 | 2014 | 200 | 0.100 |
Why?
| | Quantitative Trait, Heritable | 1 | 2014 | 118 | 0.100 |
Why?
| | Aged, 80 and over | 5 | 2025 | 8279 | 0.090 |
Why?
| | Aged | 8 | 2025 | 25947 | 0.090 |
Why?
| | Cannabis | 1 | 2019 | 509 | 0.090 |
Why?
| | Multicenter Studies as Topic | 2 | 2026 | 405 | 0.090 |
Why?
| | Anti-Bacterial Agents | 1 | 2022 | 1915 | 0.080 |
Why?
| | Sentinel Lymph Node Biopsy | 1 | 2011 | 118 | 0.080 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2017 | 2147 | 0.080 |
Why?
| | Neoplasms | 1 | 2025 | 2884 | 0.080 |
Why?
| | Asthma | 1 | 2021 | 1768 | 0.080 |
Why?
| | Inflammation | 1 | 2021 | 2880 | 0.070 |
Why?
| | Treatment Outcome | 4 | 2025 | 11695 | 0.070 |
Why?
| | Lung | 2 | 2024 | 4109 | 0.070 |
Why?
| | Lymph Nodes | 1 | 2011 | 502 | 0.070 |
Why?
| | Hospital Mortality | 2 | 2025 | 1031 | 0.070 |
Why?
| | Rats | 1 | 2017 | 5614 | 0.070 |
Why?
| | Proteins | 1 | 2014 | 1022 | 0.070 |
Why?
| | Case-Control Studies | 3 | 2025 | 3608 | 0.070 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2026 | 1721 | 0.060 |
Why?
| | Sex Characteristics | 2 | 2023 | 791 | 0.060 |
Why?
| | Surveys and Questionnaires | 3 | 2025 | 6053 | 0.060 |
Why?
| | Time Factors | 1 | 2017 | 7183 | 0.060 |
Why?
| | Alpha-Ketoglutarate-Dependent Dioxygenase FTO | 2 | 2017 | 27 | 0.060 |
Why?
| | Databases, Factual | 2 | 2023 | 1486 | 0.060 |
Why?
| | Child, Preschool | 4 | 2021 | 11799 | 0.060 |
Why?
| | Burn Units | 1 | 2025 | 48 | 0.060 |
Why?
| | Bias | 2 | 2017 | 202 | 0.050 |
Why?
| | Phthalazines | 1 | 2025 | 64 | 0.050 |
Why?
| | Pneumococcal Vaccines | 1 | 2025 | 130 | 0.050 |
Why?
| | Melanoma | 1 | 2011 | 761 | 0.050 |
Why?
| | Community-Based Participatory Research | 1 | 2025 | 166 | 0.050 |
Why?
| | Carboplatin | 1 | 2024 | 160 | 0.050 |
Why?
| | United States | 4 | 2022 | 15988 | 0.050 |
Why?
| | Immunization Programs | 1 | 2025 | 194 | 0.050 |
Why?
| | Radiopharmaceuticals | 1 | 2024 | 207 | 0.050 |
Why?
| | Paclitaxel | 1 | 2024 | 256 | 0.050 |
Why?
| | Infant | 3 | 2022 | 10039 | 0.050 |
Why?
| | Cross-Over Studies | 1 | 2025 | 601 | 0.050 |
Why?
| | Piperazines | 1 | 2025 | 381 | 0.050 |
Why?
| | Neoplasm Metastasis | 1 | 2025 | 695 | 0.050 |
Why?
| | Tryptases | 1 | 2022 | 13 | 0.050 |
Why?
| | Emergency Medical Dispatch | 1 | 2022 | 6 | 0.050 |
Why?
| | Trauma Centers | 1 | 2025 | 462 | 0.050 |
Why?
| | Substance P | 1 | 2022 | 39 | 0.040 |
Why?
| | Self Efficacy | 1 | 2025 | 414 | 0.040 |
Why?
| | Information Systems | 1 | 2022 | 57 | 0.040 |
Why?
| | Hospitalization | 2 | 2023 | 2434 | 0.040 |
Why?
| | Osteocalcin | 1 | 2021 | 38 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2023 | 5872 | 0.040 |
Why?
| | Respiratory Sounds | 1 | 2021 | 105 | 0.040 |
Why?
| | Ovulation | 1 | 2021 | 41 | 0.040 |
Why?
| | Estrous Cycle | 1 | 2021 | 23 | 0.040 |
Why?
| | Workflow | 1 | 2022 | 185 | 0.040 |
Why?
| | Rural Population | 1 | 2025 | 650 | 0.040 |
Why?
| | Collagen Type I | 1 | 2021 | 147 | 0.040 |
Why?
| | Patient Outcome Assessment | 1 | 2021 | 134 | 0.040 |
Why?
| | Endoscopy | 1 | 2023 | 316 | 0.040 |
Why?
| | Precision Medicine | 1 | 2024 | 458 | 0.040 |
Why?
| | Quality of Life | 2 | 2023 | 3192 | 0.040 |
Why?
| | Research Design | 1 | 2026 | 1137 | 0.040 |
Why?
| | Guatemala | 1 | 2020 | 345 | 0.040 |
Why?
| | Young Adult | 3 | 2025 | 14126 | 0.040 |
Why?
| | Ovary | 1 | 2021 | 228 | 0.040 |
Why?
| | Sleep Deprivation | 1 | 2021 | 206 | 0.040 |
Why?
| | Animals | 2 | 2021 | 38109 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2023 | 1990 | 0.030 |
Why?
| | Hospitals | 1 | 2023 | 732 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2022 | 1095 | 0.030 |
Why?
| | Decision Support Systems, Clinical | 1 | 2021 | 265 | 0.030 |
Why?
| | Cannabidiol | 1 | 2019 | 136 | 0.030 |
Why?
| | Body Mass Index | 2 | 2017 | 2438 | 0.030 |
Why?
| | Administration, Oral | 1 | 2019 | 848 | 0.030 |
Why?
| | Antibodies, Monoclonal | 1 | 2024 | 1524 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2023 | 1141 | 0.030 |
Why?
| | Dronabinol | 1 | 2019 | 247 | 0.030 |
Why?
| | Medicare | 1 | 2022 | 887 | 0.030 |
Why?
| | Inpatients | 1 | 2021 | 546 | 0.030 |
Why?
| | Respiration, Artificial | 1 | 2021 | 708 | 0.030 |
Why?
| | Pilot Projects | 1 | 2021 | 1890 | 0.030 |
Why?
| | Bayes Theorem | 1 | 2017 | 433 | 0.030 |
Why?
| | Algorithms | 1 | 2023 | 1839 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2022 | 1563 | 0.030 |
Why?
| | Analgesics, Opioid | 1 | 2022 | 1143 | 0.020 |
Why?
| | Prevalence | 1 | 2020 | 2836 | 0.020 |
Why?
| | Gene Frequency | 1 | 2014 | 481 | 0.020 |
Why?
| | Quality Improvement | 1 | 2021 | 1291 | 0.020 |
Why?
| | Support Vector Machine | 1 | 2011 | 36 | 0.020 |
Why?
| | Risk Assessment | 1 | 2021 | 3676 | 0.020 |
Why?
| | Exercise | 1 | 2022 | 2201 | 0.020 |
Why?
| | Biomarkers | 1 | 2021 | 4275 | 0.020 |
Why?
| | Age Factors | 1 | 2017 | 3335 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2021 | 6434 | 0.020 |
Why?
| | Neoplasm Staging | 1 | 2011 | 1465 | 0.020 |
Why?
| | Risk Factors | 1 | 2021 | 10792 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2011 | 2118 | 0.010 |
Why?
| | Phenotype | 1 | 2014 | 3164 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2014 | 2365 | 0.010 |
Why?
| | Cohort Studies | 1 | 2014 | 5965 | 0.010 |
Why?
| | Mice | 1 | 2021 | 18365 | 0.010 |
Why?
| | Prognosis | 1 | 2011 | 4293 | 0.010 |
Why?
|
|
Rice's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|